The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is involved in cellular proliferation, differentiation, and survival. It has been reported that 50-80% of AML patients have a constitutively active PI3K/mTOR pathway, which correlates with very poor prognosis. 4, 5 In addition, aberrant activation of the PI3K pathway is a feature of leukemia-initiating cells. 6, 7 Although PI3K inhibitors have been shown to target AML cells, including leukemia-initiating cells, clinical results have been disappointing, likely due to compensatory activation of other survival pathways. [8] [9] [10] Thus, PI3K inhibitors must be used in combination to prevent compensation by other survival pathways and ensure successful eradication of AML cells.
Preclinical testing has revealed promising anti-cancer activity for the combination of PI3K inhibitors with histone deacetylase (HDAC) inhibitors. [11] [12] [13] This prompted the design and synthesis of the dual PI3K and HDAC inhibitor CUDC-907 (fimepinostat). 14 CUDC-907 has shown encouraging preclinical activity against multiple types of cancers and the drug is currently being tested in phase I and II clinical trials for the treatment of lymphoma, multiple myeloma, and advanced/relapsed solid tumors (www.clinicaltrials.gov). [15] [16] [17] It has shown such promising clinical efficacy that the US Food and Drug Administration recently granted Fast Track designation to CUDC-907 for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (http://www.curis.com/). In this study, we investigated CUDC-907 in AML cell lines, primary AML samples, and a cell linederived xenograft AML model. We showed that CUDC-907 induces apoptosis in AML cell lines and primary AML samples and this effect is, at least partially, mediated by Mcl-1, Bim, and c-Myc. Additionally, CUDC-907 treatment downregulates CHK1, Wee1, and ribonucleotide reductase (RR) catalytic subunit M1 (RRM1) and induces DNA replication stress and damage. In vivo results show that CUDC-907 has potential for the treatment of AML.
Methods
A detailed description of the methods is given in the Online Supplementary Material.
Cell culture
The characteristics of the cell lines are presented in Online Supplementary Table S1 .
Clinical samples
Diagnostic AML blast samples were obtained from patients at the First Hospital of Jilin University (Changchun, China). Written informed consent was provided according to the Declaration of Helsinki. The Human Ethics Committee of the First Hospital of Jilin University approved this study. Clinical samples were screened for gene mutations by polymerase chain reaction (PCR) amplification and automated DNA sequencing, and fusion genes by real-time reverse transcriptase PCR, as described previously. 18, 19 The patients' characteristics are presented in Online Supplementary Table S2 . Samples were chosen based on availability of adequate material at the time the assay was performed.
Annexin V/propidium iodide staining
Apoptosis was determined using an Annexin V-Fluorescein Isothiocyanate (FITC)/Propidium Iodide (PI) Apoptosis Kit (Beckman Coulter; Brea, CA, USA), as described elsewhere. 20, 21 The mean percentage (± standard error of mean) of annexinV + /PI -(early apoptotic) and annexin V + /PI + (late apoptotic and/or dead) cells from one representative experiment is shown.
Colony formation assay
Cells were treated with CUDC-907 for 24 h, washed with phosphate-buffered saline, plated in triplicate in MethoCult (Stem Cell Technologies, Cambridge, MA, USA) and incubated for 10-14 days, according to the manufacturer's instructions. Colony-forming units were visualized using an inverted microscope and colonies containing >50 cells were enumerated.
Leukemia xenograft model
Immunocompromised triple transgenic NSG-SGM3 female mice at 8 weeks of age [NSGS, JAX#103062; non-obese diabetic scid gamma (NOD.Cg-Prkdc scid Il2rg tm1Wjl Tg(CMV-IL3, CSF2, KITLG)1Eav/MloySzJ; Jackson Laboratory, Bar Harbor ME, USA] were injected with MV4-11 cells (1 x 10 6 cells/mouse; 0.2 mL/injection) intravenously (day 0). Mice were randomly divided into three groups (5 mice/group; day 3): one group was the no treatment control group, the other two groups were given 100 or 150 mg/kg CUDC-907 [3% ethanol (200 proof), 1% Tween-80 (polyoxyethylene 20 sorbitan monooleate) and sterile water; all USP grade; v/v)]. Mice were treated daily for 8 days followed by 4 days off treatment, and then treated for a further 6 days. Body weights were recorded daily and condition assessed (at least twice daily) for the duration of the study. Mice were humanely euthanized when they presented with: >20% weight loss, decreased mobility limiting access to food and water, lymph node metastases, progressive anemia, or lateral recumbency. The percentage increase in lifespan (%ILS) was calculated: % ILS = [T-C/C] x 100 where "T" is the median day of death of treated mice and "C" is the median day of death of control animals. In vivo experiments were approved by the Institutional Animal Care and Use Committee at Wayne State University.
For the pharmacodynamics study, NSG mice were injected with MV4-11 cells (1 x 10 7 cells/mouse) intravenously. Twenty-one days later, mice were randomized (5 mice/group) and injected once with vehicle control, 100 or 150 mg/kg CUDC-907. The mice were sacrificed 24 h later and bone marrow cells were collected. Human cells were enriched using the EasySep Mouse/Human Chimera Isolation Kit (Stem Cell Technologies).
Statistical analysis
Differences were compared using the pair-wise two-sample ttest (comparisons of apoptosis, colony-forming units, and %DNA in the tail) or the Mann-Whitney two-sample U test [comparison of CUDC-907 half maximal inhibitory concentration (IC 50 )]. The overall survival probability was estimated using the Kaplan-Meier method and the statistical analysis was performed using the logrank test. The statistical computations were conducted using GraphPad Prism 5.0. The level of statistical significance was set at P<0.05.
Results

CUDC-907 decreases viable cells and induces apoptosis in acute myeloid leukemia cell lines, and shows promise against a MV4-11-derived xenograft model in vivo
CUDC-907 IC 50 for seven AML cell lines, as measured by MTT assays, ranged from 12.4 nM (for MOLM-13) to 73.7 nM (for CTS) ( Figure 1A ). Annexin V/PI staining and flow cytometry analysis revealed that treatment with Figure 1E ). Furthermore, overexpression of Bcl-xL abolished CUDC-907-induced apoptosis demonstrating that CUDC-907 induces apoptosis through the intrinsic apoptosis pathway ( Figure 1F ). The potential in vivo efficacy of CUDC-907 was evaluated in an early stage MV4-11-derived xenograft mouse model. Mice were treated with CUDC-907 daily for 8 days, given 4 days off treatment, and then treated daily for another 6 days ( Figure 1G ). All mice were given a 4-day break due to the 3% body weight loss in the mice treated with 150 mg/kg CUDC-907 after the initial eight doses ( Figure 1H ).
This body weight loss was completely reversible within 4 days. The median survival following CUDC-907 treatment was 44 days for the animals given the 100 mg/kg dose and 47 days for those given the 150 mg/kg, which are 11 and 14 days longer (or 33.3% and 42.2% increases in lifespan), respectively, than the median survival of the mice given the vehicle control (33 days; P=0.002) ( Figure  1I ). These results suggest that CUDC-907 treatment possesses modest antileukemic activity in vivo.
CUDC-907 treatment decreases viable cells and induces apoptosis in primary acute myeloid leukemia samples from patients
CUDC-907 IC 50 ranged from 8.1 to 1,831 nM (Online Supplementary Table S2 ) in primary AML patient samples. Interestingly, samples from patients positive for FLT3- 
CUDC-907 downregulates Mcl-1, CHK1, Wee1, and RRM1, and upregulates Bim in acute myeloid leukemia cells
As previously reported, 15 CUDC-907 treatment decreased the levels of p-AKT (both T308 and S473) in three AML cell lines and two primary AML samples ( Figure 3A ). CUDC-907 treatment also decreased p-ERK1/2 levels, while total ERK levels remained relatively unchanged. p-AKT changes were detected as early as 3 h after CUDC-907 treatment in the cell lines (Online Supplementary Figure S1 ). These results confirm that CUDC-907 inactivated the PI3K/AKT and MEK/ERK pathways at these concentrations. Total AKT levels were decreased after 24 h of CUDC-907 treatment, although 3 h of treatment caused a decrease of p-AKT in the absence of changes in total AKT (Online Supplementary Figure S1 ). Increased acetylation of histone H4 and tubulin (deacetylated by HDAC6) was detected in the AML cell lines, confirming inhibition of HDAC at these concentrations as early as 3 h after treatment ( Figure 3A and Online Supplementary Figure S1 ). Substantially increased acetylation of histone H4 was also detected in both primary AML samples, while the acetylation of tubulin was increased to a much lesser extent. Inhibition of the PI3K pathway and HDAC have been shown to cause downregulation of Mcl-1 and upregulation of Bim, respectively. [22] [23] [24] [25] Accordingly, CUDC-907 treatment caused a reduction of Mcl-1 and an increase of Bim ( Figure 3B ), while Bcl-2, Bcl-xL, Bax, and Bak protein levels remained unchanged (Online Supplementary Figure S2 ). Based on the reports that HDAC inhibitors can downregulate DNA damage response proteins, [23] [24] [25] [26] we looked at γH2AX (a potential biomarker of DNA double-strand breaks), DNA damage response proteins CHK1, Wee1, and related downstream proteins. CUDC-907 treatment caused an increase of γH2AX and decreases of CHK1, p-CDK1, p-CDK2, Wee1, and RRM1 in AML cell lines and primary AML samples ( Figure 3C ). Total CDK1 and CDK2 levels were largely unaffected. p-CDC25C and RRM2 decreased, except in U937 cells. E2F1 levels decreased in the cell lines and in one primary AML samples. These results suggest that CUDC-907 may induce DNA damage, which causes death of AML cells. The above results were further confirmed in the MV4-11 xenograft mouse model following administration of a single dose of CUDC-907 ( Figure 3D ). Downregulation of CHK1, Wee1, and RRM1 by CUDC-907 treatment was not affected by the pan-caspase inhibitor Z-VAD-FMK (Online Supplementary Figure S3 ). In contrast, Z-VAD-FMK treatment itself caused an increase in Mcl-1 protein levels, suggesting that caspases are involved in the regulation of Mcl-1 protein. Surprisingly, co-treatment of AML cells with CUDC-907 and Z-VAD-FMK resulted in substantial- Figure S3 ). Using the parental compounds of CUDC-907, SAHA (a pan-HDAC inhibitor) and GDC-0941 (a PI3K inhibitor), alone or combined (at a 1:1 ratio) at inhibitory concentrations, we found that SAHA and GDC-0941 synergistically induced apoptosis (Online Supplementary Figure S4A, C) . The half maximal effective concentrations (EC 50 ) were much higher for the combination of SAHA plus GDC-0941 than for CUDC-907, suggesting that while they do synergize, the hybrid is more potent than the parental compounds.
Western blotting analysis of whole cell lysates from MOLM-13 cells treated with CUDC-907 for up to 24 h, revealed decreased Mcl-1 and increased Bim, cleaved caspase 3, and cleaved PARP at the 12 h time-point ( Figure  4A ). Decreased RRM1 and CHK1, and increased γH2AX were also detected at the 12 h time-point, while decreased Wee1 was detected as early as 4 h after CUDC-907 treatment ( Figure 4B ). Similar protein level changes were detected 16 h after treatment in U937 cells (Online Supplementary Figure S5 ). Annexin V/PI staining revealed a significant increase in annexin V + cells, indicating that X. Li et al. 2232 haematologica | 2019; 104(11) (Figure 4C, D) . Taken together, these results suggest that these changes in protein levels coincide with the induction of apoptosis.
Mcl-1 and Bim play important roles in CUDC-907induced apoptosis
To Phosphorylation of Mcl-1 at T163 has been shown to stabilize Mcl-1 by prolonging its half-life 27 and phosphorylation at S159 enhances ubiquitylation and degradation. 28 In MOLM-13 and U937 cells, CUDC-907 treatment caused downregulation of p-Mcl-1 (T163), while p-Mcl-1 (S159) levels remained unchanged ( Figure 5H ; upper panel). Treatment with the proteasome inhibitor MG-132, prevented downregulation of Mcl-1 by CUDC-907 ( Figure  5H ; lower panel). Since ERK has been reported to phosphorylate Mcl-1 at T163 27 and CUDC-907 treatment inactivates ERK, we treated MOLM-13 cells with the ERK inhibitor SCH-772984 and found that treatment did indeed downregulate p-Mcl-1 (T163), while having little to no effect on p-Mcl-1 (S159) levels (Online Supplementary  Figure S6A ). MG-132 treatment prevented downregulation of Mcl-1 following SCH-772984 treatment (Online Supplementary Figure S6B) . Taken together, these results suggest that CUDC-907 inactivates ERK, resulting in decreased Mcl-1 stability and Mcl-1 protein levels. 
E F G H
CUDC-907 treatment induces DNA damage in acute myeloid leukemia cells but spares normal human bone marrow mononuclear cells
Western blot analysis revealed that CUDC-907 treatment substantially increased chromatin-bound RPA32 and γH2AX levels, indicating that CUDC-907 treatment induced DNA replication stress and damage ( Figure 6A, B) . Furthermore, alkaline comet assay results showed that CUDC-907 induced significant increases in DNA strand breaks, as indicated by increased %DNA in the tail (greater %DNA in the tail corresponds to increased DNA strand breaks), for both AML cell lines ( Figure 6C, D) . The pan-caspase inhibitor Z-VAD-FMK did not have an effect on the %DNA in the tail following CUDC-907 treatment, demonstrating that the increased DNA damage was not a reflection of caspase-dependent cell death (Online Figure S7) . DNA strand breaks induced by CUDC-907 were also detected in two primary AML patient samples but not in normal human bone marrow mononuclear cells ( Figure 6E ), suggesting that CUDC-907 does not induce DNA damage in normal hematopoietic cells. To determine the functional role of CHK1, Wee1, and RRM1 in apoptosis induced by CUDC-907, U937 cells were treated with CUDC-907 alone or in combination with the CHK1 inhibitor LY2603618, Wee1 inhibitor MK-1775, or the RR inhibitor hydroxyurea for 24 h. Annexin V/PI staining and flow cytometry revealed that each inhibitor significantly enhanced CUDC-907-induced apoptosis ( Figure 6F ), which suggests that CHK1, Wee1, and RRM1 also play important roles in CUDC-907induced apoptosis in the cells. Real-time reverse transcriptase PCR results showed that CUDC-907 treatment caused significant decreases of CHK1, Wee1, and RRM1 transcripts in the AML cells both in vitro and in vivo ( Figure  6G -J), suggesting that CUDC-907 downregulates CHK1, Wee1, and RRM1 expression in the cells through transcriptional regulation. While it has been reported that nonisoform selective PI3K inhibitors also inhibit DNA-PK, inhibition of DNA-PK is not likely to have contributed to the increased DNA damage-induced by CUDC-907 since its effect on DNA-PK activity was minimal (Online Supplementary Figure S8 ).
CUDC-907 downregulates c-Myc in acute myeloid leukemia cells
CUDC-907 treatment was shown to downregulate c-Myc protein in diffuse large B-cell lymphoma cells. 16 Since c-Myc is an oncoprotein that is frequently activated in AML cells and plays a role in leukemogenesis, 29, 30 we next determined the role of c-Myc in CUDC-907-induced apoptosis in AML cells. Indeed, CUDC-907 treatment decreased expression of c-Myc in AML cell lines and a primary AML sample ( Figure 7A ). In addition, decreased expression was detected in our MV4-11 xenograft mouse model following a single dose of CUDC-907 ( Figure 7B) . The pan-caspase inhibitor Z-VAD-FMK did not have an effect on downregulation of c-Myc by CUDC-907 (Online Supplementary Figure S9A ). Furthermore, treatment with SAHA, GDC-0941, and SAHA plus GDC-0941 did not reduce c-Myc protein levels, again suggesting that the hybrid is more potent than the parental compounds (Online Supplementary Figure S9B) . In both MOLM-13 and U937 cells, downregulation of c-Myc was detected as early as 4 h after CUDC-907 treatment ( Figure 7C ). c-Myc transcript levels were decreased in AML cell lines, two primary AML patient samples ( Figure 7D ) and in the MV4-11 xenograft mouse model following a single dose of CUDC-907 ( Figure 7E 
Discussion
A major hurdle in the successful treatment of AML is resistance to standard therapies, which warrants the development of novel strategies. Here, we showed that CUDC-907 has promising antileukemic activity against AML cell lines, both in vitro and in vivo, and against leukemia progenitor cells from primary AML patient samples. CUDC-907 treatment decreased expression of the anti-apoptotic protein Mcl-1 and increased expression of the pro-apoptotic protein Bim. Ectopic overexpression of Mcl-1 and shRNA knockdown of Bim demonstrated that both proteins play important roles in CUDC-907-induced apoptosis in AML cells ( Figure 5A, B) . Our results are consistent with the known effects of PI3K and HDAC inhibition, which have been shown to decrease the anti-apoptotic protein Mcl-1 and upregulate the pro-apoptotic protein Bim. [22] [23] [24] [25] In addition, they are in agreement with the findings of Rahmani et al. who demonstrated that Bim and Mcl-1 play a role in HDAC and PI3K inhibitor lethality in non-Hodgkin lymphoma. 12 Our data show that CUDC-907 treatment decreases the stability of Mcl-1, at least partially through its ability to inactivate ERK ( Figure 5D-H) . Based on the reported transcriptional regulation of Bim following HDAC inhibitor treatment 31, 32 Figure 3B ) was likely due to transcriptional regulation mediated by the HDAC inhibitor moiety of CUDC-907. However, given the evidence that the ERK pathway regulates Bim degradation, 33, 34 post-transcriptional mechanisms cannot be ruled out. Additionally, inactivation of AKT and ERK may also contribute to the antileukemic activity of CUDC-907 through other downstream targets. 12, 14 HDAC inhibitors have been shown to induce differentiation, cell cycle arrest, DNA damage, and apoptosis in AML cells. 20, 26, [35] [36] [37] One mechanism through which HDAC inhibitors exert their anticancer activity is through downregulation of DNA damage response proteins, such as CHK1 and Wee1, as we and others have reported. [23] [24] [25] [26] In agreement, we detected downregulation of CHK1 and Wee1 protein and transcript levels ( Figures 3C and 6G , I, and J). HDAC inhibitor-induced downregulation of CHK1 and Wee1 has been shown to be mediated through downregulation of E2F1. 37, 38 However, the decrease of E2F1 was not consistent in the AML cell lines and primary AML patient sample. CUDC-907 treatment caused decreases of E2F1, CHK1, and Wee1 in three AML cell lines and one primary AML patient's sample. However, in the other primary AML patient sample, CUDC-907 treatment did not result in a decrease of E2F1 protein but did decrease both CHK1 and Wee1 protein levels. These results suggest that downregulation of CHK1 and Wee1 was probably mediated through transcript regulation, though it may not have been entirely mediated through downregulation of E2F1.
CUDC-907 treatment also decreased RRM1 protein and transcript levels ( Figures 3C and 6H, J) , suggesting that downregulation of this gene was probably mediated by a transcriptional mechanism. Based on our results using hydroxyurea, RRM1 likely played an important role in CUDC-907-induced DNA damage. Inhibition of RR decreases dNTP pools, resulting in DNA replication fork stalling, impaired DNA repair, and DNA damage. 39 In agreement with Sun et al., 16 we found that CUDC-907 treatment reduced expression of c-Myc protein prior to induction of apoptosis ( Figures 4C, D and 7C ). Given its role in cell growth, proliferation, and survival, the early downregulation of c-Myc may play a more prominent role in CUDC-907-induced apoptosis since changes in CHK1, Wee1, RRM1, Bim, and Mcl-1 levels occur after c-Myc downregulation.
FLT3-ITD AML has been shown to be associated with increased DNA damage and misrepair, 40 potentially making such leukemias more sensitive to DNA replication fork stalling, impaired DNA repair, and DNA damage. Interestingly, we found that primary AML samples from patients with FLT3-ITD were significantly more sensitive to CUDC-907 ex vivo (Figure 2A ). FLT3-ITD has also been shown to constitutively activate downstream PI3K and ERK pathways, conferring resistance to PI3K and ERK inhibitors. However, HDAC inhibitors have been shown to upregulate ubiquitin conjugase 41 and inhibit HSP90 resulting in proteasomal degradation of FLT3. 42, 43 Consistent with those reports, CUDC-907 treatment did indeed decrease FLT3 protein levels in the FLT3-ITD AML cell line MOLM-13 (Online Supplementary Figure S10) . Thus, the HDAC inhibitor moiety of CUDC-907 reduces FLT3 levels, relieving constitutive activation of the PI3K and ERK pathways, and allowing the PI3K inhibitor function of CUDC-907 to induce AML cell death. This may explain the superior response of FLT3-ITD AML cells to CUDC-907 (Figure 2A ), although the effects of CUDC-907 on AML cell apoptosis, colony-formation capacity, and FLT3 protein levels need to be further elucidated in additional primary samples from patients with FLT3-ITD AML.
Results of the first phase I trial of CUDC-907 were recently published, outlining the safety, tolerability, and preliminary activity in patients with lymphoma or multiple myeloma. 17 In that study, the recommended dosing for further clinical studies was identified to be 60 mg administered orally, once daily for 5 days, followed by 2 days off treatment, as there were no dose-limiting toxicities at this dosing and schedule. In addition, side effects were consistent with the known profile of HDAC or PI3K inhibitors and deemed manageable. Our data show promising in vivo efficacy against an AML cell line-derived xenograft mouse model, supporting further clinical development of CUDC-907 as an AML-focused therapy. While modest weight loss was seen after CUDC-907 treatment (nadir: -5.4% on day 22, 2 days after last treatment), it was completely reversible within 4 days. This fact coupled with the observed modest survival benefit produced from the interrupted treatment schedule indicate that either or both the dosing and schedule can be further optimized (i.e. in hindsight, the drug was so well tolerated that the 4-day interruption of treatment may not have been necessary). Furthermore, the tolerability of CUDC-907 suggests that it may be used in combination with other therapies. Conventional chemotherapy drugs, such as cytarabine or daunorubicin, may synergize with CUDC-907 as these drugs induce DNA damage and would likely add further insult to the stressed DNA repair system following CUDC-907 treatment.
In summary, our study demonstrates that CUDC-907 induces DNA damage and apoptosis in AML cell lines and primary patients' samples, and targets AML progenitor cells while sparing normal hematopoietic cells in vitro. In addition, our initial in vivo study generated a promising increase in survival following CUDC-907 monotherapy. As a dual inhibitor, CUDC-907 lends itself to the possibility of combination therapies to further eliminate AML and prevent disease relapse. Our findings provide new insights into the mechanism of action of CUDC-907 in AML cells ( Figure 7G ) and support its clinical development for the treatment of AML.
